The Japanese Ministry of Health, Labour and Welfare has cleared Novo Nordisk's diabetes therapy, Ryzodeg.
Ryzodeg, which has been approved to be administered once or twice daily, is the global brand name for insulin degludec/insulin aspart and contains Tresiba and NovoRapid.
Tresiba is a once-daily new-generation basal insulin analogue with an ultra-long duration of action. NovoRapid is marketed under the brand name NovoLog in the US.
Novo Nordisk executive vice president and chief science officer Mads Krogsgaard Thomsen said, "The unique properties of Ryzodeg provide the potential to improve treatment for people with diabetes in Japan".
The company will make Ryzodeg available in FlexTouch, a prefilled insulin pen with auto-injector mechanism, and in Penfill for its durable insulin pens.
The diabetes therapy demonstrated a considerably lower risk of nocturnal hypoglycaemia while successfully achieving equivalent reductions in HbA1c when compared to NovoMix, in treat-to-target studies.
